Last update: Jan. 15, 2021
Minimal risk for breastfeeding and infant.
Sulfonylurea that stimulates endogenous insulin secretion. May cause hypoglycemia.
Indicated in the treatment of type 2 diabetes.
Oral administration in one or two daily doses.
Its pharmacokinetic data (moderately high molecular weight and very high percentage of plasma protein binding) explain the zero or negligible passage into breast milk observed (Feig 2005).
The infants' blood glucose levels were normal (Feig 2005).
Experts authors consider the use of this medication to be safe during breastfeeding (Serrano 2015, Glatstein 2009, Feig 2007).
Diet, exercise, and breastfeeding improve blood sugar levels.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2021 from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM